Skip to contentB
BioCorRx Inc.
B
BICXBioCorRx Inc. Q2 2024 · 10-Q
Revenue$4.05K$4.05K−79.4% vs Q2 2023 Net Income-$1.23M-$1.23MN/M vs Q2 2023 EPS Diluted-$0.13-$0.13no prior Q2 2023 on file Operating Income-$1,369,352N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
BioCorRx Inc. · CIK 1443863 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin-33853.0%−29030.4 pt vs Q2 2023
Net margin-30506.7%−25803.1 pt vs Q2 2023
ended Jun 30, 2024 · filed Aug 13, 2024 · 44 d after period end